Over the past 50 years, the survival rate for childhood brain cancer has more than doubled. According to Dr. Paul Fisher, a pediatric neurologist, we are curing brain cancer in about 68% of children. Unfortunately, survivors often face a variety of struggles, including chronic headaches, nausea, and seizures. Nearly one-third require special education.
Researchers across the United States are looking for ways to minimize the adverse effects of treatment on cognition. Recently, Andrew Zureick, a second-year medical student at the University of Michigan Medical School, was recognized for his promising research in this very important area. He is the recipient of the 2014 Lucien Rubinstein Award from the American Brain Tumor Association (ABTA).
From ABTA Press Release
He was part of a group of ten students who were awarded the ABTA Medical Student Summer Fellowship. This is a 10-to-12 week research experience offered by the ABTA to medical students with an interest in brain tumor research. Andrew's laboratory experience took place at Harvard Medical School under the supervision of Dr. Torunn Yock, Director of Pediatric Radiation Oncology at Massachusetts General Hospital Cancer Center.
Following completion of the fellowship, students are expected to submit a research report to a panel of ABTA Scientific Reviewers. The panel rates each report, and identifies one student to be the recipient of the annual ABTA Lucien Rubinstein Award. Andrew's research has furthered our understanding of the critical areas of the brain we most need to spare during therapy to best preserve neurocognition.
Congratulations to Andrew!
Learn More About The ABTA Medical Student Summer Fellowship